Resistance exercise dosage in men with prostate cancer: Systematic review, meta-analysis and meta-regression

Pedro Lopez  
*Edith Cowan University*

Dennis R. Taaffe  
*Edith Cowan University*

Robert U. Newton  
*Edith Cowan University*

Daniel A. Galvao  
*Edith Cowan University*

Follow this and additional works at: [https://ro.ecu.edu.au/ecuworkspost2013](https://ro.ecu.edu.au/ecuworkspost2013)

Part of the *Medicine and Health Sciences Commons*

Lopez, P., Taaffe, D. R., Newton, R. U., & Galvao, D. A. (2021). Resistance Exercise Dosage in Men with Prostate Cancer: Systematic Review, Meta-analysis, and Meta-regression. *Medicine and science in sports and exercise*, 53(3), 459 - 469. [https://doi.org/10.1249/MSS.0000000000002503](https://doi.org/10.1249/MSS.0000000000002503)

This Journal Article is posted at Research Online.  
[https://ro.ecu.edu.au/ecuworkspost2013/8634](https://ro.ecu.edu.au/ecuworkspost2013/8634)
Resistance Exercise Dosage in Men with Prostate Cancer: Systematic Review, Meta-analysis, and Meta-regression

PEDRO LOPEZ1,2, DENNIS R. TAAFFE1,2, ROBERT U. NEWTON1,2,3, and DANIEL A. GALVÃO1,2

1Exercise Medicine Research Institute, Edith Cowan University, Perth, Western Australia, AUSTRALIA; 2School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, AUSTRALIA; and 3School of Human Movement and Nutrition Sciences, University of Queensland, Queensland, AUSTRALIA

ABSTRACT

LOPEZ, P., D. R. TAAFFE, R. U. NEWTON, and D. A. GALVÃO. Resistance Exercise Dosage in Men with Prostate Cancer: Systematic Review, Meta-analysis, and Meta-regression. Med. Sci. Sports Exerc., Vol. 53, No. 3, pp. 459–469, 2021. Purpose: Resistance exercise improves an array of treatment-related adverse effects in men with prostate cancer; however, the minimal dosage required is unknown. We systematically reviewed the resistance training effects in prostate cancer patients to determine the minimal dosage regarding the exercise components (type, duration, volume, and intensity) on body composition, physical function, muscle strength, cardiorespiratory fitness, body mass index, and prostate-specific antigen. Methods: Using PRISMA guidelines, MEDLINE, CINAHL, EMBASE, SPORTDiscus, and Web of Science databases were searched. Eligible randomized controlled trials examined prostate cancer patients undertaking resistance-based exercise programs during or after treatment. Meta-analysis was undertaken when more than three studies were included. Associations between mean differences and exercise components were tested by univariate and multivariate meta-regression analysis. Results: Twenty-three articles describing 21 trials and involving 1748 prostate cancer patients were included. Exercise improved fat mass (~1% in body fat and ~0.6 kg in fat mass), lean mass (~0.5 kg in lean and appendicular lean mass), functional capacity (i.e., chair rise, 400-m test, 6-m fast walk, and stair climb tests), and fitness outcomes (i.e., VO2peak and muscle strength) (P = 0.040–<0.001) with no change in body mass index or prostate-specific antigen (P = 0.440–0.735). Meta-regression indicated no association between exercise type, resistance training duration, weekly volume and intensity, and primary outcomes (P = 0.075–0.965). There was a significant association between exercise intensity and chest press muscle strength (favoring moderate intensity, P = 0.012), but not in other secondary outcomes. Conclusion: In untrained older men with prostate cancer initiating an exercise program, lower volume at moderate to high intensity is as effective as higher volume resistance training for enhancing body composition, functional capacity, and muscle strength in the short term. A low exercise dosage may help reduce barriers to exercise and enhance adherence. Key Words: PROSTATE CANCER, RESISTANCE TRAINING, DOSE–RESPONSE EFFECTS, MINIMAL DOSAGE, HEALTH-RELATED OUTCOMES

The benefits of exercise medicine have been widely attested in different cancer populations (1,2). In prostate cancer patients, for example, resistance exercise alone or combined with aerobic training has been shown to reduce postsurgical impairments from prostatectomy (3), reverse the array of adverse effects from androgen deprivation therapy (ADT) (4–11), and preserve physical function in those with bone metastases (12), in addition to improvements in quality of life (5,8,12). However, although the role of exercise medicine is being expanded to include low-grade cancer patients undergoing active surveillance (13–15), or high-grade patients to enhance tumor growth suppression (16) and survival (17), information regarding the actual exercise dose–response still needs to be determined (18).

Considering the overall exercise benefits in prostate cancer patients, the assumption that a given exercise dosage will promote benefits in all outcomes is premature. In the most recent exercise guideline for cancer patients (19), a specific resistance
exercise dosage (e.g., 2 sets of 8–15 reps at 60%–85% of one-repetition maximum [1-RM]) was recommended to address or counter anxiety, fatigue, and depressive symptoms based on high-quality publications. However, the disproportionately large number of breast cancer trials compared with other cancer trials from which the recommendations were derived precludes more accurate recommendations for prostate cancer patients (19). Further, the paucity of comparative trials regarding resistance training components (i.e., frequency, intensity, and volume) makes it difficult to establish the dose–response effect on commonly reported outcomes. In this report, we examined the resistance exercise dosage in body composition and functional capacity given their strong association with risk of progression and mortality in prostate cancer patients (20–23).

Thus, the aim of the present study is 1) to systematically review and analyze the resistance training effects on body composition measures, functional capacity tests, cardiorespiratory fitness, muscle strength, body mass index (BMI), and prostate-specific antigen (PSA) levels and 2) to verify the minimal dose regarding the prescribed exercise components (i.e., type, duration, volume, and intensity) and effects on these outcomes.

METHODS

Study selection procedure. The study was undertaken in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (24,25), and the method used was based on the minimum criteria established by the Cochrane Back Review Group (26). This systematic review was not registered in any prospectively systematic review database (e.g., PROSPERO).

This review included published data from randomized controlled trials that evaluated the effects of resistance-based exercise programs in prostate cancer patients at any treatment stage (e.g., presurgical, during treatment, and with bone metastases). The primary outcomes of this review were body composition (i.e., body fat percentage, fat mass, trunk fat mass, lean mass, and appendicular lean mass) and functional capacity tests (i.e., 30-s sit-to-stand test, 6-min walk, 400-m walk, 6-m usual and fast walk, timed up-and-go, stair climb, and repeated sit-to-stand where patients repeated the task 5 times). The secondary outcomes were cardiorespiratory fitness (i.e., $\dot{V}O_{2\text{peak}}$ or $\dot{V}O_{2\text{max}}$), muscle strength (i.e., chest press, leg press, leg extension, and seated row), PSA, and BMI. Trials were excluded if 1) home-based exercise was used in the whole intervention period; 2) they involved mixed cancer patients without specific information on prostate cancer patient results; 3) they did not include or report the specific outcomes included in this review, or did not include sufficient information for analysis; and 4) they were written in a language other than English. Eligibility was assessed independently evaluated in duplicate, with differences resolved by consensus.

The search was conducted up to November 2019 using the following electronic databases: MEDLINE, CINAHL, EMBASE, SPORTDiscus, and Web of Science. The terms used were “prostate cancer” and “resistance training” in association with a list of sensitive terms to search for experimental studies. In addition, we performed a manual search of the reference lists provided in the selected articles as well as previous systematic reviews and meta-analytic studies (27–32) to detect studies potentially eligible for inclusion. The search strategy used is shown in Table S1 (see Supplemental Digital Content 1, Literature search strategy used for the PubMed database, http://links.lww.com/MSS/C125).

Data extraction. Titles and abstracts of all articles identified by the search strategy were independently evaluated in duplicate. Abstracts that did not provide sufficient information regarding the inclusion and exclusion criteria were selected for full-text evaluation. In the second phase, the same reviewers independently evaluated these full-text articles and selected them in accordance with the eligibility criteria. Disagreements between reviewers were resolved by consensus. The data extraction was performed via a standardized form. Information on the interventions, outcomes, and patients were collected. Study characteristics, intervention duration, components of the resistance training prescription (i.e., frequency, intensity, volume, and type), adherence (i.e., number of patients that completed the program), attendance (i.e., number of sessions attended), compliance (i.e., number of patients that successfully completed the exercise prescription), and adverse events were extracted, along with the main outcomes. The prescribed resistance training was summarized as follows: frequency (number of sessions per week), intensity (prescribed intensity of resistance training), type (resistance training, combined resistance and aerobic training, or multimodal exercise program), and volume (sets and repetitions). When studies incorporated supervised and unsupervised periods of training, information was extracted on the longest period of the supervised exercise intervention. Outcomes were extracted in their absolute units (e.g., kilograms for lean and fat mass assessments). When graphs were used instead of numerical data, the graphs were measured through their plots using a specific tool for data extraction (WebPlotDigitizer, San Francisco, CA) (33).

Assessment of risk of bias. Risk of bias of individual studies was evaluated according to the second version of the Cochrane risk of bias tool for randomized trials (RoB 2) (34), focusing on different aspects of the trial design, conduct, and reporting. Each assessment using the RoB 2 tool is focused at the outcome level. The six-item instrument evaluates 1) randomization process, 2) deviation from intended interventions, 3) missing outcome data, 4) measurement of the outcome, 5) selection of the reported result, and 6) overall bias, and it was used to evaluate each included randomized controlled trial for each outcome of interest. Risk of bias for each of the six domains was expressed as “low risk,” “some concern,” and “high risk” (34).

Data analysis. The pooled-effect estimates were obtained from the mean difference of baseline to the final assessment of the intervention for each group. These values were expressed as the mean difference between groups. In studies with multiple exercise interventions, the groups were divided with each respective sample size, within-group mean difference, and SD or 95% confidence interval (CI) for further analysis. Meta-analyses were conducted for overall studies, and a subgroup analysis was provided based on RoB 2.0 low-risk
classification when more than three studies were included. Calculations were performed using a random-effects model (35). The level of significance was set at \( P \leq 0.05 \). Statistical heterogeneity was assessed using the Cochran \( Q \) test. A threshold \( P \) value of 0.1 as well as values greater than 50% in the statistical test of heterogeneity \( (I^2) \) were considered indicative of high heterogeneity (36). Heterogeneity between studies was explored by omitting one study at a time and comparing the pooled with the original estimates, whereas the presence of publication bias was explored by contour-enhanced funnel plots along with Egger’s test, considering a \( P \) value <0.1 as indicative of publication bias (37,38). When necessary, the trim-and-fill computation was used to estimate the effect of publication bias on the interpretation of results (39,40). Analyses were conducted using the package metan, confunnel, metabias, and metatrim from Stata 14.0 software (Stata, College Station, TX). Forest plots presented for the outcome measures are after sensitivity analysis and/or trim-and-fill procedure adjustments.

In addition, we tested the association between the mean difference effect and the exercise components to identify a dose–response relationship using univariate and multivariate meta-regression. Using one variable at a time or multivariable models, we assessed whether components such as type, intervention duration, prescribed weekly volume, and peak intensity influence the association of resistance-based exercise with the main effects. Analyses were undertaken in outcomes significantly affected by exercise provided the models had more than five studies. For intervention duration, prescribed weekly volume, and peak intensity, analyses were considered when the values presented a range higher than 5%, whereas exercise type was coded as 0 = resistance training alone and 1 = resistance training combined with other components (e.g., aerobic, flexibility, impact loading, or balance). Analyses were conducted using the package metareg from Stata 14.0 software.

**RESULTS**

**Studies included.** All studies selected reported the aim to investigate the effect of resistance training (i.e., resistance training alone, combined with aerobic exercise, or included in a multimodal exercise program) in prostate cancer patients at any treatment stage. We retrieved 1021 studies, 794 of which were retained for screening after duplicate removals. Of these, 694 were excluded and 100 full-text articles were assessed for eligibility (Fig. 1). The eligibility assessment resulted in 23 articles (describing 21 trials) (5–12,41–55), which were included in the present review and meta-analyses (see Table S2, Supplemental Digital Content 2, Study characteristics: treatment stage, sample size, exercise prescription, adherence, attendance, compliance and outcomes assessed, http://links.lww.com/MSS/C126), with 6 to 13 studies being included in the dose–response relationship analysis involving exercise type, intervention duration, prescribed weekly volume, and peak intensity.

**Prostate cancer patients and exercise intervention characteristics.** A total of 1748 prostate cancer patients with an average age of 69.5 ± 2.1 yr participated in the included studies. Exercise interventions were predominantly undertaken in patients on ADT (17 of 23 studies) (5,7–9,11,41,43–48,
Exercise modality included predominantly combined resistance and aerobic training (12 of 23 studies (5–7,9,10,41,43,45,50–52,55) followed by multimodal exercise program (4 of 23 studies) (11,12,48,54), resistance training plus impact loading (5 of 23 studies) (7,9,44,46,49), and resistance training only (4 of 23 studies) (8,42,47,53) in a cohort of 901 patients allocated to the intervention group compared with 847 patients in the control group. In addition, three studies (41,43,48) also provided nutrition advice during the intervention. Studies were designed to compare the exercise intervention versus usual care control (15 of 23 studies) (5,8,11,12,41,43,45,47,50,51,53), whereas 14 studies (6,10,44,46,53,54) or to a delayed exercise group (2 of 23 studies) (7,9). Two studies compared multiple exercise interventions (7,9).

The mean exercise intervention duration was 19.5 ± 10.7 wk with an average of 2.4 ± 0.7 sessions per week. The average total prescribed resistance training volume was 9136 ± 4534 repetitions with a weekly training volume of 468 ± 177 repetitions. In addition, the mean peak intensity reached throughout the resistance training program was 79% ± 8% of 1-RM ranging from 60% to 85%. Information about resistance training frequency was not reported by one study (53), whereas four studies did not report volume (41,43,48,54) or intensity (41,50,54,55), respectively. Exercise program adherence ranged from 74% to 100% (reported in 22 of 23 studies) (5–9,11,12,41–55), whereas attendance and compliance ranged from 65% to 100% (reported in 21 of 23 studies) (5–12,41,42,44–46,48–55) and from 85% to 94% (reported in 5 of 23 studies) (41,42,47,49,53), respectively. Adverse events related to the exercise interventions were identified in 8 studies (6,8,9,45,47,50,51,54), whereas 14 studies (5,7,11,12,41–44,46,48,49,52,53,55) reported no adverse events throughout the intervention period. The adverse events were mostly related to musculoskeletal pain (e.g., back, shoulder, and knee), and only one study (53) presented a moderate adverse event with no detail provided.

**Risk of bias assessment.** For the primary outcomes of this review, 13.3% of the studies presented some concern for risk of bias in body composition assessment (2 of 15 studies) (48,55) and 76.9% in the functional capacity tests (10 of 13 studies) (5,6,9,12,42,45,47,50,51,53). The concerns in body composition were mainly due to the measurement of the outcome as two studies (48,55) evaluated body composition outcome, whereas 14 studies (5,7,11,12,41–44,46,48,49,52,53,55) reported no adverse events throughout the intervention period. For the secondary outcomes, concerns were observed in cardiorespiratory fitness (some concerns: 60.0%, 3 of 5 studies) (43,53,54), muscle strength (84.6%, 11 of 13 studies) (5–8,10,12,42,45,47,50,53), and BMI (16.7%, 1 of 6 studies) (47). Concerns were not observed in the PSA assessment. The overall risk of bias assessment is shown in Table S3 (see Supplemental Digital Content 3, Risk of bias of included studies, http://links.lww.com/MSS/C127), and the individual assessment is presented in Figure S1 (see Supplemental Digital Content 4, Individual risk of bias assessment, http://links.lww.com/MSS/C128).

**Exercise effects on body composition.** Exercise resulted in significant positive overall effects in percent body fat (−1.0%, 95% CI = −1.3 to −0.6%), fat mass (−0.6 kg, 95% CI = −0.8 to −0.3 kg), trunk fat mass (−0.3 kg, 95% CI = −0.6 to −0.2 kg), lean mass (0.5 kg, 95% CI = 0.3 to 0.7 kg), and appendicular lean mass (0.4 kg, 95% CI = 0.2 to 0.6 kg) with heterogeneity ranging from $I^2 = 0\%$ to 47\% after sensitivity analysis and/or trim-and-fill procedure adjustments (Figs. 2 and 3). The samples ranged from 490 to 917 participants (see Table S4, Supplemental Digital Content 5, Overall and subgroup analysis effects on body composition, functional capacity, and the secondary outcomes in prostate cancer patients, http://links.lww.com/MSS/C129). In subgroup analysis, the main effects were significantly maintained in the outcomes ($I^2 = 0\%$ to 47\%; $P = <0.001$ to 0.025). Outliers were identified in the overall analysis for body fat percentage (6) and trunk fat mass (52) and subgroup analysis of appendicular lean mass (7), whereas publication bias and trim-and-fill procedure suggested that data from three studies were missing for appendicular lean mass ($P = 0.050$). These studies were omitted from the abovementioned overall and subgroup effects (Figs. 2 and 3). The meta-analysis power to detect changes in body composition was $\beta = 1.0$.

In the dose–response analysis, the univariate ($P = 0.075$ to 0.965; see Table S5, Supplemental Digital Content 6, Univariate meta-regression on main outcomes mean difference and exercise type, resistance training duration, weekly volume and peak intensity, http://links.lww.com/MSS/C130) and multivariate meta-regression models ($P = 0.203$ to 0.785; see Table S6, Supplemental Digital Content 7, Multivariate meta-regression on main outcomes mean difference and exercise type, resistance training duration, weekly volume and peak intensity, http://links.lww.com/MSS/C131) did not explain the variation in body composition outcomes.

**Exercise effects on functional capacity.** There was a significant positive overall exercise effect for the time to perform the 30-s sit-to-stand repetitions (2.8 reps, 95% CI = 1.7 to 4.0 reps), repeated sit-to-stand test (−1.0 s, 95% CI = −1.4 to −0.6 s), 400-m walk (−8.3 s, 95% CI = −12.4 to −4.2 s), 6-m fast walk (−0.1 s, 95% CI = −0.2 to −0.0), and stair climb (−0.2 s, 95% CI = −0.3 to −0.1 s) with a heterogeneity ranging from $I^2 = 0\%$ to 45.2\% after sensitivity analysis and/or trim-and-fill procedure adjustments (Fig. 4). The samples ranged from 213 to 519 participants (see Table S4, Supplemental Digital Content 5, Overall and subgroup analysis effects on body composition, functional capacity, and the secondary outcomes in prostate cancer patients, http://links.lww.com/MSS/C129). Subgroup analyses were not undertaken on these outcomes as well as the overall analyses in the 6-min walk test and 6-m backwards walk test given the small number of studies included (<3). The study of Galvão et al. (12) was considered
an outlier in the 6-m fast walk time analysis and omitted from the abovementioned results, whereas publication bias was only found for the 400-m walk (\(P = 0.063\)) with no trimming needed to be performed (data unchanged). The meta-analysis power to detect change in the 6-m usual walk and timed up-and-go test was \(1 - \beta = 0.57\) and 0.64, respectively, whereas a \(1 - \beta = 1.0\) was found for the remaining functional capacity outcomes.

In the dose–response analysis, the univariate (\(P = 0.182\) to 0.341; see Table S5, Supplemental Digital Content 6, Univariate meta-regression on main outcomes mean difference and exercise type, resistance training duration, weekly volume and peak intensity, http://links.lww.com/MSS/C130) and multivariate meta-regression models (\(P = 0.358\); see Table S6, Supplemental Digital Content 7, Multivariate meta-regression on main outcomes mean difference and exercise type, resistance training duration, weekly volume and peak intensity, http://links.lww.com/MSS/C131) were not statistically significant in explaining the variation in 400-m test performance. Analyses of 30-s
FIGURE 3—Mean difference effects of resistance-based exercise compared with control on lean mass (A) and appendicular lean mass (B). Overall and subgroup analyses conducted with a random-effects model. Gray and white circles represent study-specific estimates based on risk of bias assessment (low risk and some concern or high risk of bias, respectively); I² represents the heterogeneity test; diamonds represent pooled estimates of random-effect meta-analysis. *Combined resistance and aerobic group. #Resistance training plus impact-loading group.

Exercise effects on secondary outcomes. There was a significant increase in chest press (3.9 kg, 95% CI = 2.9 to 4.9 kg), leg press (23.5 kg, 95% CI = 15.2 to 31.7 kg), leg extension (8.8 kg, 95% CI = 6.9 to 10.7 kg), and seated row strength (5.2 kg, 95% CI = 3.9 to 6.5 kg) with heterogeneity ranging from $I^2 = 0\%$ to $77.4\%$ after sensitivity analysis and/or trim-and-fill procedure adjustments (Fig. 5). The samples ranged from 321 to 728 participants (see Table S4, Supplemental Digital Content 5, Overall and subgroup analysis effects on body composition, functional capacity, and the secondary outcomes in prostate cancer patients, http://links.lww.com/MSS/C129). Subgroup analyses were not undertaken for these outcomes because of the small number of studies that were considered of low risk ($\leq$3). Outliers were identified in the overall analysis for chest press (8), leg extension (12), and seated row test (53). Meta-analysis power to detect change in muscle strength was $1 - \beta = 1.0$.

Regarding VO$_2$peak, there was a positive overall effect of 1.3 mL·kg$^{-1}$·min$^{-1}$ (95% CI = 0.8 to 1.7 mL·kg$^{-1}$·min$^{-1}$) after the publication bias and trim-and-fill procedure, suggesting that data were missing from two studies ($P = 0.078$; see Table S4, Supplemental Digital Content 5, Overall and subgroup analysis effects on body composition, functional capacity, and the secondary outcomes in prostate cancer patients, http://links.lww.com/MSS/C129, and Fig. 6). Finally, exercise did not result in a significant change in BMI or PSA levels ($P = 0.440$–0.735; see Table S4, Supplemental Digital Content 5, Overall and subgroup analysis effects on body composition, functional capacity, and the secondary outcomes in prostate cancer patients, http://links.lww.com/MSS/C129, and Fig. 6). Meta-analysis power to detect change in VO$_2$peak was $1 - \beta = 1.0$, whereas power for BMI and PSA was 0.25 and 0.57, respectively.

In the univariate dose–response analysis, resistance training type and intensity ($r^2 = 64.0\%$, $P = 0.010$, and $r^2 = 100\%$, $P < 0.001$, respectively; see Table S5, Supplemental Digital Content 6, Univariate meta-regression on main outcomes mean difference and exercise type, resistance training duration, weekly volume and peak intensity, http://links.lww.com/MSS/C130) explained the variation in chest press muscle strength. In the multivariate model, gain in chest press muscle strength ($r^2 = 100\%$, $P = 0.012$; see Table S6, Supplemental Digital Content 7, Multivariate meta-regression on main outcomes mean difference and exercise type, resistance training duration, weekly volume and peak intensity, http://links.lww.com/MSS/C131) was greater in studies prescribing resistance training with moderate intensity ($P = 0.022$). Although the resistance training volume was significant in the univariate model to explain leg extension and leg press muscle strength ($P = 0.043$ and 0.050, respectively; see Table S5, Supplemental Digital Content 6, Univariate meta-regression on main outcomes mean difference and exercise type, resistance training duration, weekly volume and peak intensity, http://links.lww.com/MSS/C130), the results were not maintained in the multivariate meta-regression model ($P = 0.147$–0.204). Dose–response analyses of VO$_2$peak and the seated row test were not undertaken because of the small number of studies ($\leq$5) reporting on these components. Performing univariate meta-regression resulted in nonsignificant associations between exercise type, resistance training duration, weekly volume, and peak intensity with VO$_2$peak, and the seated row test was explained by exercise type (coefficient ± SE; $-14.9 \pm 2.9$, $P = 0.014$; favoring resistance training alone), resistance training weekly volume ($0.0 \pm 0.1$, $P = 0.032$; favoring higher weekly volume), but not resistance training duration ($P = 0.624$; see Table S5, Supplemental Digital Content 6, Univariate meta-regression on main outcomes mean difference and exercise type, resistance training duration, weekly volume and peak intensity, http://links.lww.com/MSS/C130).

DISCUSSION

The present review produced four important findings in prostate cancer patients. First, body composition is enhanced...
by resistance exercise (i.e., increase in whole body and regional lean mass and decrease in fat mass) regardless of type, duration, weekly volume, and peak intensity. Second, exercise promotes significant improvements in multiple components of physical function, in a nonlinear dose–response fashion. Third, muscle strength and cardiorespiratory fitness are improved with exercise, with greater effects in chest press strength resulting from resistance training performed at a moderate intensity. Finally,
Resistance-based exercise does not modify BMI or affect PSA levels. Therefore, the resistance training prescription combined with different exercise components is a potent therapy against an array of treatment-related adverse effects in prostate cancer patients regardless of the weekly volume prescribed when moderate to high intensity is achieved.

Obesity has been associated with an increased risk of biochemical recurrence and mortality in prostate cancer patients in a dose–response fashion (20). In the meta-analysis by Cao and Ma (20), a 5-kg·m\(^{-2}\) increase in BMI was associated with a 21% increased risk for biochemical recurrence and a 20% increased risk for prostate cancer–specific mortality. In our study, PSA levels did not change in response to exercise involving resistance training, indicating no impact of this exercise mode on disease progression (e.g., albeit not expected to change as most studies were short in duration with the majority of patients having local disease). In addition, few studies reported adverse events, and these were generally minor in nature. Moreover, the similar magnitude of change observed in lean mass and fat mass (i.e., increase in lean mass and decrease in fat mass) accounts for the maintenance in BMI and may result in metabolic health benefits and enhanced survival (56,57). Furthermore, the lack of relationship between resistance training weekly volume, intensity, and duration indicates the potential benefit of low-dosage resistance training to improve overall body composition. Likewise, in a previous report by Stamatakis et al. (58), a low weekly dosage of resistance training was associated with an approximately 25% reduced risk of mortality. Thus, undertaking exercise programs that include resistance training not only results in benefits for body composition in men with prostate cancer but also may provide a protective effect against cancer recurrence and cancer-specific adverse events.
mortality even when performed at a low weekly dosage. These results are of importance for prostate cancer patients and the prescription of exercise for this patient group as it suggests that even modest amounts of exercise may result in the accrual of significant body composition benefits, and this may also contribute to increased attendance and compliance to an exercise program.

Considering the World Health Organization report (59), the concept of healthy aging should be seen as the process of developing and maintaining functional capacity. Several studies report the association between muscle strength, cardiorespiratory fitness, and functional tests with independence, hospitalization, and mortality (60–65). Thus, the observed gains in muscle strength, cardiorespiratory fitness, and functional capacity support the translation of exercise medicine effects into functional independence and autonomy in older prostate cancer patients. For example, the reduction in time to walk 400 m represents an increase in the safety margin before the threshold for disability and may help to reduce the risk for complications such as risk for falls and fractures (66,67) and mortality (21). Reduced risk of mortality is also associated with enhanced repeated sit-to-stand and stair climb test performance (22,23). In this way, the progression of moderate to high intensity in resistance training combined with other exercise components appears to be sufficient to achieve significant improvements in functional capacity of patients with prostate cancer regardless of the number of weekly repetitions. Thus, the present findings provide an appropriate approach for prostate cancer patients as it allows a conservative exercise prescription commencement (e.g., less repetitions per exercise at moderate to high loads) and gradual progression according to comorbidities and the patient’s treatment-related side effects (68). Furthermore, following the nonsignificant relationship between intervention duration and study outcomes, it is also possible to maintain a low-dosage resistance training program for longer periods, which may help patients to keep active during and after treatment.

One of the critical considerations in the design of exercise trials and of its potential and feasibility in cancer patients is related to the exercise dose–response (18,19,68). However, to date, the assessment and the quantification of exercise dosage as well as the lack of reporting preclude a minimal-dosage prescription for prostate cancer patients. The present review and analysis provide information that less repetitions per exercise at moderate to high intensity (i.e., 60%–85% of 1-RM) could be sufficient to achieve significant benefits for prostate cancer patients, at least in the short term. We hypothesize that because of the large window for adaptation in these undeveloped qualities, these men adapt at a similar rate within the volumes and intensities of the studies analyzed, at least over the relatively short duration of these interventions. Our results partially agree with previous studies comparing different resistance training dosages in older adults (69–71), with similar results for various dosages after 12 wk of training (69,71) but not for longer training periods such as 20 wk (70,71). This could be due to the lower threshold for muscular adaptations in untrained older participants in the initial stages of training and the need for a greater stimulus after this initial period. However, the lack of influence of intervention duration suggests the potential use of low-volume resistance training during longer periods in prostate cancer patients, different than that observed in healthy older adults (70,71). Future studies will be necessary to elucidate if higher dosage and longer duration accrue greater benefits in prostate cancer patients. Furthermore, considering the meta-analytic adjustments and heterogeneity, the positive exercise results observed in body composition and multiple components of physical function are likely to be observed across different treatment phases (e.g., during ADT or after primary treatment). Given the lower between-studies heterogeneity in the meta-analysis ($I^2 <$ 30%), the observed results in body fat, muscle mass, 6-min walk, 400-m walk, stair climb, repeated sit-to-stand, and cardiorespiratory fitness indicate that prostate cancer patients may experience similar benefits in these outcomes regardless of the treatment phase. Thus, the low-resistance training dosage could be a useful strategy to improve body composition and muscle function in patients at different treatment stages.

The strength of this review and analysis is that it included a large number of exercise trials encompassing prostate cancer patients at different disease stages (21 trials reported in 23 articles with 1748 patients included) in a conservative approach using univariate and multivariate meta-regression models, as well as sensitivity analysis to explore the common objectively assessed physical health-related outcomes. However, there are also some limitations that are worthy of comment. First, although our findings indicate a minimal dosage for health-related outcomes based on studies undertaken to date, it should not be seen as an “optimal” dosage for each of the outcomes investigated. Second, the use of prescribed dosage (not the actual dosage undertaken) may be considered a limitation in the present study. Although the compliance ranges from 65% to 94% in the included studies (41,42,47,49,53), most did not report this metric, precluding a determination of how much exercise was actually undertaken in the attended sessions. We recently reported on compliance in an exercise trial on men with prostate cancer who had bone metastases (72) and outlined the methodology and metrics that can be used in future studies. Finally, the exercise program duration was considered short in most of the included studies. Only two articles from the same trial (44,46) lasted longer than 6 months, and as a result, it is difficult to infer our results regarding exercise dosage beyond a period of 24 wk in duration. Future trials involving longer exercise durations will be necessary to confirm these results.

In conclusion, the results indicate that there is no difference in effect when prescribing low- and high-volume or moderate- and high-intensity resistance exercise in untrained older men with prostate cancer on body composition, functional capacity, and muscle strength outcomes, at least in the short term. Considering the array of benefits observed in the present study, a low-resistance training weekly volume could represent a time-efficient approach during and after active treatment, resulting in higher adherence, attendance, and compliance while accruing similar health and function benefits to that of higher volume exercise. We suggest the examination of resistance training
dose–response in future trials to determine whether a minimal dose approach could culminate in substantial cancer-related benefits.

Pedro Lopez is supported by the National Health and Medical Research Council (NHMRC) Centre of Research Excellence (CRE) in Prostate Cancer Survivorship Scholarship. Daniel A. Galvão and Robert U. Newton are funded by an NHMRC CRE in Prostate Cancer Survivorship. The results of the study are presented clearly, honestly, without fabrication, falsification, or inappropriate data manipulation and do not constitute endorsement by the American College of Sports Medicine.

REFERENCES

1. Schmitz KH, Courneya KS, Matthews C, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010;42(7):1409–26.
2. Schmitz KH, Campbell AM, Stuiver MM, et al. Exercise is medicine in oncology: engaging clinicians to help patients move through cancer. CA Cancer J Clin. 2019;69(6):468–84.
3. Singh F, Newton RU, Baker MK, et al. Feasibility of presurgical exercise in men with prostate cancer undergoing prostatectomy. Integr Cancer Ther. 2017;16(3):290–9.
4. Galvão DA, Newton RU, Taaffe DR, Spyr N. Can exercise ameliorate the increased risk of cardiovascular disease and diabetes associated with ADT? Nat Clin Pract Urol. 2008;5(6):306–7.
5. Galvão DA, Taaffe DR, Spyr N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol. 2010;28(2):340–7.
6. Galvão DA, Spyr N, Denham J, et al. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. Eur Urol. 2014;65(5):856–64.
7. Newton RU, Galvão DA, Spyr N, et al. Exercise mode specificity for preserving spine and hip bone mineral density in prostate cancer patients. Med Sci Sports Exerc. 2019;51(4):607–14.
8. Segal RJ, Reid RD, Courneya KS, et al. Randomised controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol. 2009;27(3):344–51.
9. Taaffe DR, Newton RU, Spyr N, et al. Effects of different exercise modalities on fatigue in prostate cancer patients undergoing androgen deprivation therapy: a year-long randomised controlled trial. Eur Urol. 2017;72(2):293–9.
10. Taaffe DR, Buffart LM, Newton RU, et al. Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer. BJU Int. 2018;121(2):194–202.
11. Taaffe DR, Galvão DA, Spyr N, et al. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition. BJU Int. 2019;123(2):261–9.
12. Galvão DA, Taaffe DR, Spyr N, et al. Exercise preserves physical function in prostate cancer patients with bone metastases. Med Sci Sports Exerc. 2012;44(3):393–399.
13. Galvão DA, Taaffe DR, Spyr N, et al. Enhancing active surveillance of prostate cancer: the potential of exercise medicine. Nat Rev Urol. 2016;13(5):258–65.
14. Galvão DA, Hayne D, Frydenberg M, et al. Can exercise delay transition to active therapy in men with low-grade prostate cancer? A multicentre randomised controlled trial. BMJ Open. 2018;8(4):e022331.
15. Kang DW, Fairey AS, Boulé NG, Field CJ, Courneya KS. Exercise during active surveillance for prostate cancer—the ERASE trial: a study protocol of a phase II randomised controlled trial. BMJ Open. 2019;9(7):e026438.
16. Hart NH, Newton RU, Spyr NA, et al. Can exercise suppress tumour growth in advanced prostate cancer patients with sclerotic bone metastases? A randomised, controlled study protocol examining feasibility, safety and efficacy. BMJ Open. 2017;7(5):e014458.
17. Newton RU, Kenfield SA, Hart NH, et al. Intense exercise for survival among men with metastatic castrate-resistant prostate cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. BMJ Open. 2018;8(5):e022899.
18. The Lancet Oncology. Exercise and cancer treatment: balancing patient needs. Lancet Oncol. 2018;19(6):715.
19. Schmitz KH, Courneya KS, Matthews C, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010;42(7):1409–26.
20. Schmitz KH, Courneya KS, Matthews C, et al. Exercise is medicine in oncology: engaging clinicians to help patients move through cancer. CA Cancer J Clin. 2019;69(6):468–84.
21. Singh F, Newton RU, Baker MK, et al. Feasibility of presurgical exercise in men with prostate cancer undergoing prostatectomy. Integr Cancer Ther. 2017;16(3):290–9.
22. Galvão DA, Newton RU, Taaffe DR, Spyr N. Can exercise ameliorate the increased risk of cardiovascular disease and diabetes associated with ADT? Nat Clin Pract Urol. 2008;5(6):306–7.
23. Newton RU, Galvão DA, Spyr N, et al. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol. 2010;28(2):340–7.
24. Galvão DA, Spyr N, Denham J, et al. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. Eur Urol. 2014;65(5):856–64.
25. Newton RU, Galvão DA, Spyr N, et al. Exercise mode specificity for preserving spine and hip bone mineral density in prostate cancer patients. Med Sci Sports Exerc. 2019;51(4):607–14.
26. Segal RJ, Reid RD, Courneya KS, et al. Randomised controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol. 2009;27(3):344–51.
27. Taaffe DR, Newton RU, Spyr N, et al. Effects of different exercise modalities on fatigue in prostate cancer patients undergoing androgen deprivation therapy: a year-long randomised controlled trial. Eur Urol. 2017;72(2):293–9.
28. Taaffe DR, Buffart LM, Newton RU, et al. Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer. BJU Int. 2018;121(2):194–202.
29. Taaffe DR, Galvão DA, Spyr N, et al. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition. BJU Int. 2019;123(2):261–9.
30. Galvão DA, Taaffe DR, Spyr N, et al. Exercise preserves physical function in prostate cancer patients with bone metastases. Med Sci Sports Exerc. 2012;44(3):393–399.
31. Galvão DA, Taaffe DR, Spyr N, et al. Enhancing active surveillance of prostate cancer: the potential of exercise medicine. Nat Rev Urol. 2016;13(5):258–65.
32. Galvão DA, Hayne D, Frydenberg M, et al. Can exercise delay transition to active therapy in men with low-grade prostate cancer? A multicentre randomised controlled trial. BMJ Open. 2018;8(4):e022331.
33. Kang DW, Fairey AS, Boulé NG, Field CJ, Courneya KS. Exercise during active surveillance for prostate cancer—the ERASE trial: a study protocol of a phase II randomised controlled trial. BMJ Open. 2019;9(7):e026438.
34. Hart NH, Newton RU, Spyr NA, et al. Can exercise suppress tumour growth in advanced prostate cancer patients with sclerotic bone metastases? A randomised, controlled study protocol examining feasibility, safety and efficacy. BMJ Open. 2017;7(5):e014458.
androgen deprivation therapy: an update meta-analysis. *Medicine (Baltimore)*. 2017;56(27):e7068.

33. Forouz D, Fura SR, Malcolm AL. Intercoder reliability and validity of WebPlotDigitizer in extracting graphed data. *Behav Modif*. 2017; 41(2):323–39.

34. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019;366:14988.

35. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7(3):177–88.

36. Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). Cochrane. 2019.

37. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315(7109):629–34.

38. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. *J Clin Epidemiol*. 2008;61(10):991–6.

39. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327(7414):557–60.

40. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics*. 2000;56(2):455–63.

41. Bourke L, Doll H, Crank H, Daley A, Rosario D, Saxton JM. Lifestyle changes for improving muscle quality in prostate cancer survivors: a feasibility study. *Cancer Epidemiol Biomarkers Prev*. 2011;20(4):647–57.

42. Cormie P, Newton RU, Spry N, Joseph D, Taaffe DR, Galvão DA. High volume strength training for prostate cancer survivors and spouses: results from a randomized controlled trial. *BJU Int*. 2015;115(2):256–66.

43. Winters-Stone KM, Dobek JC, Bennett JA, et al. Resistance training reduces disability in prostate cancer survivors on androgen deprivation therapy: evidence from a randomized controlled trial. *Arch Phys Med Rehabil*. 2015;96(1):7–14.

44. Nilsen TS, Raastad T, Skovlund E, et al. Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy. *Acta Oncol*. 2015;54(10):1805–13.

45. Gilbert SE, Tew GA, Fairhurst C, et al. Effects of a lifestyle intervention on endothelial function in men on long-term androgen deprivation therapy for prostate cancer. *Br J Cancer*. 2016;114(4):401–8.

46. Winter-Stone KM, Lyons KS, Dobek J, et al. Benefits of partnered strength training for prostate cancer survivors and spouses: results from a randomized controlled trial of the exercising together project. *J Cancer Surviv*. 2016;10(4):633–44.

47. Gaskin CJ, Fraser SF, Owen PJ, Crake M, Orellana L, Livingston PM. Fitness outcomes from a randomised controlled trial of exercise training for men with prostate cancer: the ENGAGE study. *J Cancer Surviv*. 2016;10(6):972–80.

48. H taken K, Kwiatkowska-Borowczyk E, Leporowska E, Milecki P. Inflammation, cardiometabolic markers, and functional changes in men with prostate cancer: a randomized controlled trial of a 12-month exercise program. *Pol Arch Intern Med*. 2017;127(1):25–35.

49. Wall BA, Galvão DA, Fathee N, et al. Exercise improves VO2max and body composition in androgen deprivation therapy-treated prostate cancer patients. *Med Sci Sports Exerc*. 2017;49(8):1503–10.

50. Dawson JK, Dorff TB, Todd Schroeder E, Lane CJ, Gross ME, Diel-Conwright CM. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial. *BMJ Cancer*. 2018;19(1):368.

51. Aliabhai SMH, Santa Mina D, Rito P, et al. A phase II randomized controlled trial of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy. *BMJ Cancer*. 2019;19(1):2.

52. Ndjavera W, Orange ST, O’Doherty AF, et al. Exercise-induced attenuation of treatment side-effects in patients with newly diagnosed prostate cancer beginning androgen-deprivation therapy: a randomised controlled trial. *BJU Int*. 2020;125(1):28–37.

53. Csepedes Feliciano EM, Kroenke CH, Bradshaw PT, et al. Postdischarge weight change and survival following a diagnosis of early-stage breast cancer. *Cancer Epidemiol Biomarkers Prev*. 2017;26(1):44–50.

54. Tanaka M, Okada H, Hashimoto Y, et al. Relationship between metabolic syndrome and trunk muscle quality as well as quantity evaluated by computed tomography. *Clin Nutr*. 2013;32(6):1818–25.

55. Stamatakis E, Lee IM, Bennie J, et al. Does strength-promoting exercise confer unique health benefits? A pooled analysis of data on 11 population cohorts with all-cause, cancer, and cardiovascular mortality endpoints. *Am J Epidemiol*. 2018;187(5):1102–12.

56. Beard JR, Officer AM, Cassels AK. The world report on ageing and health. *Gerontology*. 2016;56(2 Suppl):S163–6.

57. Guralnik MJ, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. *J Gerontol*. 1994;49(2):M85–94.

58. Simonsick EM, LaFerreyre M, Phillips KL, et al. Risk due to inactivity in physically capable older adults. *Am J Public Health*. 1993;83(10):1443–50.

59. Spirduso WW, Cronin DL. Exercise dose–response effects on quality of life and independent living in older adults. *Med Sci Sports Exerc*. 2001;33(6 Suppl):S598–608.

60. Jensen MT, Holtermann A, Bay H, Gyllenberg F. Cardiorespiratory fitness and death from cancer: a 42-year follow-up from the Copenhagen male study. *Br J Sports Med*. 2017;51(18):1364–9.

61. Kim Y, White T, Wijndaele K, et al. The combination of cardiorespiratory fitness and muscle strength, and mortality risk. *Eur J Epidemiol*. 2018;33(10):953–64.

62. Versteege KS, Blauwhof-Buskermolen S, Buffart LM, et al. Higher muscle mass is associated with prolonged survival in older patients with advanced cancer. *Oncologist*. 2018;23(3):580–5.

63. Shainin VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. *N Engl J Med*. 2005;352(2):154–64.

64. Ward PR, Wong MD, Moore R, Naeim A. Fall-related injuries in elderly cancer patients treated with neurotoxic chemotherapy: a retrospective cohort study. *J Geriatr Oncol*. 2014;5(1):57–64.

65. Hayes SC, Newton RU, Spence RR, Galvão DA. The Exercise and Sports Science Australia Position Statement: exercise medicine in cancer management. *J Sci Med Sport*. 2017;20(11):1175–99.

66. Cunha PM, Nunes JP, Tomelen CM, et al. Resistance training performed with single and multiple sets induces similar improvements in muscular strength, muscle mass, muscle quality, and IGF-1 in older women: a randomized controlled trial. *J Strength Cond Res*. 2020;34(4):1008–16.

67. Galvão DA, Taaffe DR. Resistance exercise dosage in older adults: single- versus multiset effects on physical performance and body composition. *J Am Geriatr Soc*. 2005;53(12):2090–7.

68. Radaelli R, Botton CE, Wilhelm EN, et al. Time course of low- and high-volume strength training on neuromuscular adaptations and muscle quality in older women. *Age (Dordr)*. 2014;36(2):881–92.

69. Hoffman CM, Nilsen TS, Newton RU, et al. Reporting of resistance training dose, adherence, and tolerance in exercise oncology. *Med Sci Sports Exerc*. 2020;52(2):315–22.